Cancer Drug Trastuzumab And Its Biosimilars Compete On Price For Market Share

Area of Science:

• Oncology
• Pharmacoeconomics
• Health Services Research

Background:

• Trastuzumab (Herceptin) is a critical targeted therapy for HER2-positive cancers.
• The introduction of biosimilars aims to increase patient access and reduce healthcare costs.
• Understanding market dynamics of originator biologics and their biosimilars is crucial for healthcare policy.

Purpose of the Study:

• To analyze US prescribing patterns of originator biologic trastuzumab and its five biosimilar entrants since 2019.
• To evaluate the impact of biosimilar competition on market share and pricing.
• To assess the evolution of market dominance and competitive pressures over time.

Main Methods:

• Utilized Medicare claims data to track prescribing patterns.
• Analyzed market share and average sales prices (ASPs) for originator trastuzumab and its biosimilars.
• Examined temporal trends in product adoption and state-level market dynamics.

Main Results:

• The first trastuzumab biosimilar rapidly captured a significant market share.
• Average sales prices for all trastuzumab products (originator and biosimilars) declined over time.
• Subsequent biosimilar entrants gained market dominance in certain states, intensifying competition.
• Brand loyalty to the initial biosimilar was observed but challenged by new market entrants.

Conclusions:

• The US market for trastuzumab biosimilars demonstrates dynamic shifts in market share and pricing.
• Increased competition from multiple biosimilar entrants leads to price erosion and evolving market leadership.
• These findings highlight the complex interplay between biosimilar entry, pricing, and market competition in oncology therapeutics.